- Home
- XHG vs IBO Comparison
XHG vs IBO Comparison
Compare XHG & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHG
- IBO
- Stock Information
- Founded
- XHG 2012
- IBO 2018
- Country
- XHG China
- IBO United States
- Employees
- XHG N/A
- IBO N/A
- Industry
- XHG
- IBO
- Sector
- XHG
- IBO
- Exchange
- XHG NYSE
- IBO NYSE
- Market Cap
- XHG 15.0M
- IBO 16.5M
- IPO Year
- XHG 2019
- IBO 2024
- Fundamental
- Price
- XHG $1.61
- IBO $2.99
- Analyst Decision
- XHG
- IBO
- Analyst Count
- XHG 0
- IBO 0
- Target Price
- XHG N/A
- IBO N/A
- AVG Volume (30 Days)
- XHG 89.4K
- IBO 68.2K
- Earning Date
- XHG 11-29-2024
- IBO 11-12-2024
- Dividend Yield
- XHG N/A
- IBO N/A
- EPS Growth
- XHG N/A
- IBO N/A
- EPS
- XHG 210.47
- IBO 0.01
- Revenue
- XHG $10,628,627.00
- IBO N/A
- Revenue This Year
- XHG N/A
- IBO N/A
- Revenue Next Year
- XHG N/A
- IBO N/A
- P/E Ratio
- XHG $0.21
- IBO $247.47
- Revenue Growth
- XHG N/A
- IBO N/A
- 52 Week Low
- XHG $1.42
- IBO $1.22
- 52 Week High
- XHG $224.00
- IBO $3.20
- Technical
- Relative Strength Index (RSI)
- XHG 29.78
- IBO N/A
- Support Level
- XHG $1.42
- IBO N/A
- Resistance Level
- XHG $2.74
- IBO N/A
- Average True Range (ATR)
- XHG 0.35
- IBO 0.00
- MACD
- XHG 0.19
- IBO 0.00
- Stochastic Oscillator
- XHG 7.68
- IBO 0.00
About XHG XCHANGE TEC.INC SPON ADS EACH REP 600000 SHS(POST SPLIT)
XChange Tec Inc, through its subsidiaries operates in insurance agency and insurance technology business. Its insurance products include industry and/or state-owned property and casualty insurance and regional property and casualty insurance. The insurance technology business is focused on operating and developing insurance technology in the PRC, including developing SaaS platform to connect consumers and underwriting support.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.